Cite
HARVARD Citation
Carlsen, A. et al. (2018). Subtherapeutic concentrations of infliximab and adalimumab are associated with increased disease activity in Crohn's disease. Therapeutic advances in gastroenterology. p. . [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
Carlsen, A. et al. (2018). Subtherapeutic concentrations of infliximab and adalimumab are associated with increased disease activity in Crohn's disease. Therapeutic advances in gastroenterology. p. . [Online].